Mga Batayang Estadistika
| CIK | 1579695 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Biotie Therapies Corp.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| February 7, 2017 |
15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specifie |
|
| January 30, 2017 |
S-8 POS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT NO. 333-206484 UNDER THE SECURITIES ACT OF 1933 BIOTIE THERAPIES OYJ (Exact name of registrant as specified in its charter) Republic of Finland Not Applicable (State or other jurisdiction of incorporation or organization) (IRS Employer Identification Num |
|
| September 30, 2016 |
EX-99.1 2 dp68139ex9901.htm EXHIBIT 99.1 Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 30 September 2016, at 2.15 p.m. (EET) ACORDA THERAPEUTICS, INC. GAINS TITLE TO ALL SHARES IN BIOTIE THERAPIES CORP. AND THE SHARES WILL DELIST FROM NASDAQ HELSINKI Acorda Therapeutics, Inc. (Nasdaq: ACOR) (”Acorda”) has today lodged security approved by the Arbitral Tribunal and thus gained title to |
|
| September 30, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant’s name into Engli |
|
| September 26, 2016 |
EX-99.1 2 dp68929ex9901.htm EXHIBIT 99.1 Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 26 September 2016, at 9.30 a.m. (EET) THE ARBITRAL TRIBUNAL HAS CONFIRMED ACORDA THERAPEUTICS, INC.'S REDEMPTION RIGHT REGARDING THE SHARES IN BIOTIE THERAPIES CORP. AND PUBLIC TRADING IN THE SHARES HAS BEEN TERMINATED The Arbitral Tribunal appointed by the Redemption Committee of the Finland Chambe |
|
| September 26, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant’s name into Engli |
|
| August 26, 2016 |
Biotie: BTT1023 receives Orphan Drug Designation in the United States EX-99.1 2 dp68144ex9901.htm FORM EX-99.1 Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 26 August 2016 at 2.30 p.m. (EET) Biotie: BTT1023 receives Orphan Drug Designation in the United States The United States Food and Drug Administration (FDA) has granted Orphan Drug Designation in the United States for Biotie’s BTT1023 drug candidate for the treatment of primary sclerosing cholangiti |
|
| August 26, 2016 |
Biotie: BTT1023 receives Orphan Drug Designation in the United States EX-99.1 2 dp68144ex9901.htm FORM EX-99.1 Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 26 August 2016 at 2.30 p.m. (EET) Biotie: BTT1023 receives Orphan Drug Designation in the United States The United States Food and Drug Administration (FDA) has granted Orphan Drug Designation in the United States for Biotie’s BTT1023 drug candidate for the treatment of primary sclerosing cholangiti |
|
| August 26, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) 6-K 1 dp681446k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of re |
|
| August 25, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) 6-K 1 dp681276k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of re |
|
| August 25, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) 6-K 1 dp681276k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of re |
|
| August 25, 2016 |
THE LISTING COMMITTEE OF NASDAQ HELSINKI HAS RESOLVED TO DELIST THE SHARES OF BIOTIE THERAPIES CORP. Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 25 August 2016, at 2.15 p.m. (EET) THE LISTING COMMITTEE OF NASDAQ HELSINKI HAS RESOLVED TO DELIST THE SHARES OF BIOTIE THERAPIES CORP. The Listing Committee of Nasdaq Helsinki Ltd ("Nasdaq Helsinki") has today, 25 August 2016, resolved to terminate public trading and to delist Biotie Therapies Corp.'s (Nasdaq Helsinki: BTH1V) (?Biotie?) s |
|
| August 25, 2016 |
THE LISTING COMMITTEE OF NASDAQ HELSINKI HAS RESOLVED TO DELIST THE SHARES OF BIOTIE THERAPIES CORP. Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 25 August 2016, at 2.15 p.m. (EET) THE LISTING COMMITTEE OF NASDAQ HELSINKI HAS RESOLVED TO DELIST THE SHARES OF BIOTIE THERAPIES CORP. The Listing Committee of Nasdaq Helsinki Ltd ("Nasdaq Helsinki") has today, 25 August 2016, resolved to terminate public trading and to delist Biotie Therapies Corp.'s (Nasdaq Helsinki: BTH1V) (?Biotie?) s |
|
| August 18, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant’s name into English) |
|
| August 18, 2016 |
BIOTIE THERAPIES CORP. APPLIES FOR DELISTING OF ITS SHARES FROM NASDAQ HELSINKI EX-99.1 2 dp68005ex9901.htm EXHIBIT 99.1 Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 18 August 2016, at 9.55 a.m. (EET) BIOTIE THERAPIES CORP. APPLIES FOR DELISTING OF ITS SHARES FROM NASDAQ HELSINKI Biotie Therapies Corp.'s (Nasdaq Helsinki: BTH1V) (“Biotie”) Board of Directors has decided to apply for the termination of public trading in Biotie shares and for the delisting of all |
|
| August 18, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant’s name into English) |
|
| August 18, 2016 |
BIOTIE THERAPIES CORP. APPLIES FOR DELISTING OF ITS SHARES FROM NASDAQ HELSINKI EX-99.1 2 dp68005ex9901.htm EXHIBIT 99.1 Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 18 August 2016, at 9.55 a.m. (EET) BIOTIE THERAPIES CORP. APPLIES FOR DELISTING OF ITS SHARES FROM NASDAQ HELSINKI Biotie Therapies Corp.'s (Nasdaq Helsinki: BTH1V) (“Biotie”) Board of Directors has decided to apply for the termination of public trading in Biotie shares and for the delisting of all |
|
| July 28, 2016 |
For the three month period ended June 30, EX-99.1 2 dp67494ex9901.htm EXHIBIT 99.1 Exhibit 99.1 BIOTIE THERAPIES CORP. INTERIM REPORT July 28, 2016 at 9.00 a.m. Biotie Therapies Corp.’s Interim Report for the reporting period January 1 – June 30, 2016 Biotie Therapies Corp. (Biotie or the Company) (Nasdaq Helsinki: BTH1V) announces its interim report for the six month period ended June 30, 2016. Company Highlights April – June 2016 · On J |
|
| July 28, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant’s name into English) J |
|
| July 19, 2016 |
EX-99.1 2 dp67263ex9901.htm EXHIBIT 99.1 Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 19 July 2016, at 9.00 a.m. (EET) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, HONG KONG OR IN ANY OTHER JURISDICTION IN WHICH THE PUBLICATION OR DISTRIBUTION OF THIS RELEASE WOULD VIOLATE APPLICABLE REGULATION OR WOULD REQUI |
|
| July 19, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant’s name into English) J |
|
| June 30, 2016 |
EX-99.1 2 dp66825ex9901.htm EXHIBIT 99.1 Exhibiy 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 29 June 2016, at 9.15 a.m. (EET) CHANGES IN THE MANAGEMENT TEAM Timo Veromaa, President and CEO of Biotie Therapies Corp. (“Biotie”, the “Company”) David Cook, CFO and Stephen Bandak, CMO of Biotie are leaving the Company by June 30, 2016. The Board of Directors of Biotie has appointed Antero Kallio |
|
| June 30, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant?s name into English) J |
|
| June 21, 2016 |
Change in Biotie Therapies' Financial Reporting Calendar 2016 EX-99.1 2 dp66647ex9901.htm EXHIBIT 99.1 Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 21 June 2016, at 5.00 p.m. Change in Biotie Therapies' Financial Reporting Calendar 2016 Due to Biotie Therapies Corp. (Nasdaq Helsinki: BTH1V) (“Biotie” or “Company”) aligning its financial reporting calendar with the financial reporting calendar of Acorda Therapeutics, Inc., the Company announces |
|
| June 21, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant’s name into English) J |
|
| June 13, 2016 |
Biotie Therapies 6-K (Current Report of Foreign Issuer) 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrants name into Englis |
|
| June 13, 2016 |
BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 13 June 2016, at 4:30 p.m. (EET) EX-99.1 2 d214027dex991.htm EX-99.1 Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 13 June 2016, at 4:30 p.m. (EET) BIOTIE THERAPIES CORP. ANNOUNCES THAT THE DELISTING OF ITS AMERICAN DEPOSITARY SHARES FROM NASDAQ GLOBAL SELECT MARKET HAS BECOME EFFECTIVE Biotie Therapies Corp. (Nasdaq Helsinki: BTH1V) (“Biotie” or the “Company”) announces that the voluntary delisting of its American D |
|
| June 13, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) 6-K 1 dp664726k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of regi |
|
| June 13, 2016 |
BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 13 June 2016, at 4.30 p.m. (EET) EX-99.1 2 dp664729901.htm EXHIBIT 99.1 Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 13 June 2016, at 4.30 p.m. (EET) BIOTIE THERAPIES CORP. ANNOUNCES THAT THE DELISTING OF ITS AMERICAN DEPOSITARY SHARES FROM NASDAQ GLOBAL SELECT MARKET HAS BECOME EFFECTIVE Biotie Therapies Corp. (Nasdaq Helsinki: BTH1V) (“Biotie” or the “Company”) announces that the voluntary delisting of its America |
|
| June 10, 2016 |
Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 10 June 2016, at 8.00 a.m. (EET) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, HONG KONG OR IN ANY OTHER JURISDICTION IN WHICH THE PUBLICATION OR DISTRIBUTION OF THIS RELEASE WOULD VIOLATE APPLICABLE REGULATION OR WOULD REQUIRE ADDITIONAL MEASURES IN ADDITION TO THE |
|
| June 10, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) 6-K 1 dp664456k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of regi |
|
| June 2, 2016 |
Form 25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-37423 Biotie Therapies Oyj (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) Joukahaisenkatu 6, FI-20 |
|
| May 18, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) 6-K 1 dp658206k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of regis |
|
| May 18, 2016 |
BIOTIE THERAPIES CORP. TO DELIST ITS AMERICAN DEPOSITARY SHARES FROM THE NASDAQ GLOBAL SELECT MARKET Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 18 May 2016, at 9.00 a.m. (EET) BIOTIE THERAPIES CORP. TO DELIST ITS AMERICAN DEPOSITARY SHARES FROM THE NASDAQ GLOBAL SELECT MARKET Biotie Therapies Corp.’s (Nasdaq Helsinki: BTH1V; Nasdaq: BITI) (“Biotie”) Board of Directors has on 17 May 2016 resolved to voluntarily delist its American Depositary Shares (“ADSs”), each representing 80 Bi |
|
| May 18, 2016 |
BIOTIE THERAPIES CORP. CANCELS ALL TREASURY SHARES HELD BY THE COMPANY EX-99.2 3 dp65820ex9902.htm EXHIBIT 99.2 Exhibit 99.2 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 18 May 2016, at 9.00 a.m. (EET) BIOTIE THERAPIES CORP. CANCELS ALL TREASURY SHARES HELD BY THE COMPANY Biotie Therapies Corp.’s (Nasdaq Helsinki: BTH1V; Nasdaq: BITI) (“Biotie” or the “Company”) Board of Directors has today resolved to cancel all 106,088,336 treasury shares held by the Company (the |
|
| May 18, 2016 |
NORDEA BANK FINLAND PLC’S MARKET-MAKING FOR BIOTIE THERAPIES CORP.’S SHARE ENDS EX-99.3 4 dp65820ex9903.htm EXHIBIT 99.3 Exhibit 99.3 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 18 May 2016, at 6.20 p.m. (EET) NORDEA BANK FINLAND PLC’S MARKET-MAKING FOR BIOTIE THERAPIES CORP.’S SHARE ENDS Biotie Therapies Corp. (“Biotie”) and Nordea Bank Finland Plc (“Nordea”) have jointly agreed to terminate the market-making agreement entered into between Biotie and Nordea on 21 September |
|
| May 12, 2016 |
Biotie Interim Report 1 January - 31 March 2016 EX-99.1 2 dp65679ex9901.htm EXHIBIT 99.1 Exhibit 99.1 BIOTIE THERAPIES CORP. INTERIM REPORT May 12, 2016 at 9.00 a.m. Biotie Interim Report 1 January - 31 March 2016 Biotie (Nasdaq Helsinki: BTH1V; NASDAQ: BITI) announces its interim report for the three month period ended March 31, 2016. Company Highlights January – March 2016 · On January 19, 2016 Biotie announced that it entered into a combinat |
|
| May 12, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) 6-K 1 dp656796k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of regis |
|
| May 4, 2016 |
Biotie Therapies AMENDMENT NO. 9 TO SC TO-T SC TO-T/A 1 d168762dsctota.htm AMENDMENT NO. 9 TO SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 9) BIOTIE THERAPIES OYJ (Name of Subject Company (issuer)) ACORDA THERAPEUTICS, INC. (Name of Filing Person (offeror)) Ordinary shares, no nominal |
|
| May 4, 2016 |
Amendment No. 1 to Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1) BIOTIE THERAPIES OYJ (Name of Issuer) Ordinary shares, no nominal value (“Ordinary Shares”) (Title of Class of Securities) FI0009011571 (Ordinary Shares) (CUSIP Number of Class of Securities) Jane Wasman President, Intern |
|
| May 3, 2016 |
RESOLUTIONS OF THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP. AND ORGANIZATION OF THE BOARD EX-99.1 2 dp65526ex9901.htm EXHIBIT 99.1 Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 3 May 2016 at 4.30 p.m. RESOLUTIONS OF THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP. AND ORGANIZATION OF THE BOARD The Annual General Meeting of Biotie Therapies Corp. was held on 3 May 2016. Adoption of financial statements for the financial year 1 January - 31 December 2015 and booking of t |
|
| May 3, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) 6-K 1 dp655266k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of regis |
|
| May 2, 2016 |
Biotie Therapies FORM SC 14D9/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) (Amendment No. 5) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOTIE THERAPIES OYJ (Name of Subject Company) BIOTIE THERAPIES OYJ (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), each re |
|
| May 2, 2016 |
EX-99.1 2 dp65420ex9901.htm EXHIBIT 99.1 Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 2 May 2016, at 4.40 p.m.(EET) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, HONG KONG OR IN ANY OTHER JURISDICTION IN WHICH THE TENDER OFFER WOULD BE PROHIBITED BY APPLICABLE LAW. FINAL RESULTS OF THE SUBSEQUENT OFFER PERIOD |
|
| May 2, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) 6-K 1 dp654206k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of regis |
|
| May 2, 2016 |
Biotie Therapies AMENDMENT NO. 8 TO SC TO-T Amendment No. 8 to SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 8) BIOTIE THERAPIES OYJ (Name of Subject Company (Issuer)) ACORDA THERAPEUTICS, INC. (Name of Filing Person (Offeror)) Ordinary shares, no nominal value (?Ordinary Shares?) Amer |
|
| May 2, 2016 |
EX-99.(A)(5)(G) 2 d172698dex99a5g.htm EX-99.(A)(5)(G) Exhibit (a)(5)(G) ACORDA THERAPEUTICS, INC. PRESS RELEASE 2 May 2016 at 4:00 p.m. (EET) / 9:00 a.m. (New York Time) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, HONG KONG OR IN ANY OTHER JURISDICTION IN WHICH THE TENDER OFFER WOULD BE PROHIBITED BY APPLICABLE LAW. FINAL |
|
| April 25, 2016 |
BITI / Biotie Therapies Corp. / ACORDA THERAPEUTICS INC - SCHEDULE 13D Activist Investment Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 BIOTIE THERAPIES OYJ (Name of Issuer) Ordinary shares, no nominal value (“Ordinary Shares”) (Title of Class of Securities) FI0009011571 (Ordinary Shares) (CUSIP Number of Class of Securities) Jane Wasman President, International, General Counsel and Corporate |
|
| April 20, 2016 |
Biotie Therapies FORM SC 14D9/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) (Amendment No. 4) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOTIE THERAPIES OYJ (Name of Subject Company) BIOTIE THERAPIES OYJ (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), each re |
|
| April 20, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) 6-K 1 dp650816k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of reg |
|
| April 20, 2016 |
EX-99.1 2 dp65081ex9901.htm EXHIBIT 99.1 Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 20 April 2016, at 4.50 p.m. (EET) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, HONG KONG OR IN ANY OTHER JURISDICTION IN WHICH THE TENDER OFFER WOULD BE PROHIBITED BY APPLICABLE LAW. ACORDA THERAPEUTICS TO COMMENCE A COMPULS |
|
| April 20, 2016 |
EX-99.(A)(5)(F) 2 d185587dex99a5f.htm EX-99.(A)(5)(F) Exhibit (a)(5)(F) BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 20 April 2016, at 4.50 p.m. (EET) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, HONG KONG OR IN ANY OTHER JURISDICTION IN WHICH THE TENDER OFFER WOULD BE PROHIBITED BY APPLICABLE LAW. ACORDA THERAPEUTICS TO |
|
| April 20, 2016 |
Biotie Therapies AMENDMENT NO. 7 TO SC TO-T Amendment No. 7 to SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 7) BIOTIE THERAPIES OYJ (Name of Subject Company (issuer)) ACORDA THERAPEUTICS, INC. (Name of Filing Person (offeror)) Ordinary shares, no nominal value (?Ordinary Shares?) Amer |
|
| April 20, 2016 |
Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act EX-99.1 2 dp65083ex9901.htm EXHIBIT 99.1 Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE April 20, 2016 at 4.30 p.m. Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act Biotie Therapies Corp. (Nasdaq Helsinki BTH1V; NASDAQ: BITI) ("Biotie" or the "Company") has on April 20, 2016 received a notification in accordance with Chapter 9, Section 5 of the Finnish Securi |
|
| April 20, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant’s name into English) |
|
| April 18, 2016 |
Dear Shareholder of Biotie Therapies, EX-99.(A)(1)(P) 2 d161641dex99a1p.htm EX-99.(A)(1)(P) Exhibit (a)(1)(P) Dear Shareholder of Biotie Therapies, Acorda Therapeutics Inc.’s public Tender Offer to purchase the shares and other securities of Biotie Therapies was approved within the actual offer period which expired on 8 April 2016 by holders of equity interests, who represent 93.77% of all Biotie shares and votes (on a fully diluted b |
|
| April 18, 2016 |
EX-99.(A)(5)(E) 3 d161641dex99a5e.htm EX-99.(A)(5)(E) Exhibit (a)(5)(E) ACORDA THERAPEUTICS, INC. PRESS RELEASE 18 April 2016 at 11:00 p.m. (EET) / 4:00 p.m. (New York Time) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, HONG KONG OR IN ANY OTHER JURISDICTION IN WHICH THE TENDER OFFER WOULD BE PROHIBITED BY APPLICABLE LAW. C |
|
| April 18, 2016 |
Biotie Therapies AMENDMENT NO. 6 TO SC TO-T Amendment No. 6 to SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 6) BIOTIE THERAPIES OYJ (Name of Subject Company (issuer)) ACORDA THERAPEUTICS, INC. (Name of Filing Person (Offeror)) Ordinary shares, no nominal value (?Ordinary Shares?) Amer |
|
| April 15, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 5) BIOTIE THERAPIES OYJ (Name of Subject Company (Issuer)) ACORDA THERAPEUTICS, INC. (Name of Filing Person (Offeror)) Ordinary shares, no nominal value (?Ordinary Shares?) American Depositary Shares (?AD |
|
| April 15, 2016 |
EX-99.(A)(1)(O) 2 d179019dex99a1o.htm EX-99.(A)(1)(O) Exhibit (a)(1)(O) ACORDA THERAPEUTICS’ TENDER OFFER FOR ALL THE EQUITY INTERESTS IN BIOTIE Subsequent Offer Period 14.–28.4.2016 The Tender Offer Document is available in branch offices of OP and at op.fi/merkinta, http://ir.acorda.com/investors/Biotie-Therapies-Tender-Offer and biotie.com/investors ACORDA THERAPEUTICS’ TENDER OFFER FOR ALL THE |
|
| April 15, 2016 |
BITI / Biotie Therapies Corp. / Vivo Capital VIII, LLC - SC 13G/A Passive Investment SC 13G/A SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Biotie Therapies Corp. (Name of Issuer) American Depository Shares (Title of Class of Securities) 09074D103 (CUSIP Number) April 11, 2016 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ¨ Rule 13d-1(b) x Rule 13d-1(c) ¨ |
|
| April 14, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) 6-K 1 dp649936k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of reg |
|
| April 14, 2016 |
Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE April 14, 2016 at 11.15 p.m. Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act Biotie Therapies Corp. (Nasdaq Helsinki BTH1V; NASDAQ: BITI) ("Biotie" or the "Company") has on April 14, 2016 received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act (?SMA?) from Acorda The |
|
| April 13, 2016 |
Biotie Therapies FORM SC 14D9/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) (Amendment No. 3) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOTIE THERAPIES OYJ (Name of Subject Company) BIOTIE THERAPIES OYJ (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), each re |
|
| April 13, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) 6-K 1 dp649686k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of reg |
|
| April 13, 2016 |
Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 13 April 2016, at 5.10 p.m (EET) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, HONG KONG OR IN ANY OTHER JURISDICTION IN WHICH THE TENDER OFFER WOULD BE PROHIBITED BY APPLICABLE LAW. FINAL RESULTS OF ACORDA THERAPEUTICS' VOLUNTARY TENDER OFFER FOR ALL OF THE ISSUED |
|
| April 13, 2016 |
Biotie Therapies AMENDMENT NO. 4 TO SC TO-T Amendment No. 4 to SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 4) BIOTIE THERAPIES OYJ (Name of Subject Company (Issuer)) ACORDA THERAPEUTICS, INC. (Name of Filing Person (Offeror)) Ordinary shares, no nominal value (?Ordinary Shares?) Amer |
|
| April 13, 2016 |
EX-99.(A)(5)(D) 2 d137455dex99a5d.htm EX-99.(A)(5)(D) Exhibit (a)(5)(D) ACORDA THERAPEUTICS, INC. PRESS RELEASE 13 April 2016 at 4:00 p.m. (EET) / 9:00 a.m. (New York Time) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, HONG KONG OR IN ANY OTHER JURISDICTION IN WHICH THE TENDER OFFER WOULD BE PROHIBITED BY APPLICABLE LAW. FI |
|
| April 13, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) 6-K 1 dp649596k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of reg |
|
| April 13, 2016 |
Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act Exhibit 99.2 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 12 April, 2016 at 11.20 p.m. Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act Biotie Therapies Corp. (Nasdaq Helsinki BTH1V; NASDAQ: BITI) ("Biotie" or the "Company") has on April 12, 2016 received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act (?SMA?) from Mr. Samuel |
|
| April 13, 2016 |
Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE April 12, 2016 at 11.10 p.m. Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act Biotie Therapies Corp. (Nasdaq Helsinki BTH1V; NASDAQ: BITI) ("Biotie" or the "Company") has on April 12, 2016 received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act (?SMA?) from Acorda The |
|
| April 13, 2016 |
Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act EX-99.3 4 dp64959ex9903.htm EXHIBIT 99.3 Exhibit 99.3 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE April 12, 2016 at 11.30 p.m. Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act Biotie Therapies Corp. (Nasdaq Helsinki BTH1V; NASDAQ: BITI) ("Biotie" or the "Company") has on April 12, 2016 received a notification in accordance with Chapter 9, Section 5 of the Finnish Secur |
|
| April 13, 2016 |
EX-99.A 2 exa.htm EXHIBIT A EXHIBIT A JOINT FILING AGREEMENT In accordance with Rule 13d-1 (k)(I) under the Securities Exchange Act of 1934, as amended, each of the undersigned Reporting Persons hereby agrees to the joint filing, along with all other such Reporting Persons, on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to beneficial ownership |
|
| April 13, 2016 |
BITI / Biotie Therapies Corp. / Baupost Group LLC/MA - NONE Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 01 )* Biotie Therapies Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 09074D103 (CUSIP Number) Seth A. Klarman, The Baupost Group, L.L.C. 10 ST JAMES AVE, SUITE 1700 BOSTON, Massachusetts 02116 Phone : 617-210-8300 (Name, Address and Tele |
|
| April 13, 2016 |
BITI / Biotie Therapies Corp. / ORBIMED ADVISORS LLC - 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| April 12, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant’s name into English) |
|
| April 12, 2016 |
INVITATION TO THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP. EX-99.1 2 dp64950ex9901.htm EXHIBIT 99.1 Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 12 April 2016 at 9.00 a.m. (EET) INVITATION TO THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP. Notice is given to the shareholders of Biotie Therapies Corp. of the Annual General Meeting of the company to be held on 3 May 2016 at 2.00 p.m. (Finnish time) at Joukahaisenkatu 3-5 (ICT-building, Al |
|
| April 12, 2016 |
Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act Exhibit 99.4 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE April 12, 2016 at 4.20 p.m. Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act Biotie Therapies Corp. (Nasdaq Helsinki BTH1V; NASDAQ: BITI) ("Biotie" or the "Company") has on April 11, 2016 received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act from Vivo Capital VIII, |
|
| April 12, 2016 |
Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act EX-99.2 3 dp64950ex9902.htm EXHIBIT 99.2 Exhibit 99.2 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE April 12, 2016 at 4.10 p.m. Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act Biotie Therapies Corp. (Nasdaq Helsinki BTH1V; NASDAQ: BITI) ("Biotie" or the "Company") has on April 11, 2016 received a notification in accordance with Chapter 9, Section 5 of the Finnish Securi |
|
| April 12, 2016 |
Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act Exhibit 99.3 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE April 12, 2016 at 4.15 p.m. Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act Biotie Therapies Corp. (Nasdaq Helsinki BTH1V; NASDAQ: BITI) ("Biotie" or the "Company") has on April 11, 2016 received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act from Versant Ventures V, |
|
| April 11, 2016 |
Biotie Therapies FORM SC 14D9/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) (Amendment No. 2) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOTIE THERAPIES OYJ (Name of Subject Company) BIOTIE THERAPIES OYJ (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), each re |
|
| April 11, 2016 |
EX-99.1 2 dp64926ex9901.htm EXHIBIT 99.1 Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 11 April 2016, at 5.00 pm (EET) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, HONG KONG OR IN ANY OTHER JURISDICTION IN WHICH THE TENDER OFFER WOULD BE PROHIBITED BY APPLICABLE LAW. ACORDA THERAPEUTICS ANNOUNCES PRELIMINARY T |
|
| April 11, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant’s name into English) |
|
| April 11, 2016 |
11 April 2016 at 3:55 p.m. (EET) / 8:55 a.m. (New York Time) EX-99.(a)(5)(C) Exhibit (a)(5)(C) ACORDA THERAPEUTICS, INC. PRESS RELEASE 11 April 2016 at 3:55 p.m. (EET) / 8:55 a.m. (New York Time) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, HONG KONG OR IN ANY OTHER JURISDICTION IN WHICH THE TENDER OFFER WOULD BE PROHIBITED BY APPLICABLE LAW. ACORDA THERAPEUTICS ANNOUNCES PRELIMINAR |
|
| April 11, 2016 |
Biotie Therapies AMENDMENT NO. 3 TO SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) BIOTIE THERAPIES OYJ (Name of Subject Company (Issuer)) ACORDA THERAPEUTICS, INC. (Name of Filing Person (Offeror)) Ordinary shares, no nominal value (Ordinary Shares) American Depositary Shares (AD |
|
| March 22, 2016 |
Biotie Therapies Corp Financial statements 2015 Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 22 March 2016, at 2.20 pm (EET) ACORDA SUPPLEMENTS THE TENDER OFFER DOCUMENT RELATING TO THE VOLUNTARY PUBLIC TENDER OFFER FOR ALL OF THE ISSUED AND OUTSTANDING SHARES, AMERICAN DEPOSITARY SHARES, STOCK OPTIONS, SHARE UNITS AND WARRANTS IN BIOTIE ON 22 MARCH 2016 Biotie Therapies Corp. ("Biotie" or the "Company") announced on 10 March 2016 |
|
| March 22, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant’s name into English) |
|
| March 22, 2016 |
Biotie Therapies FORM SC 14D9/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) (Amendment No. 1) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOTIE THERAPIES OYJ (Name of Subject Company) BIOTIE THERAPIES OYJ (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), each re |
|
| March 22, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 22, 2016 |
Biotie Therapies Corp Financial statements 2015 EX-99.1 2 dp64398ex9901.htm EXHIBIT 99.1 Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE March 22, 2016 at 10 a.m. Biotie’s Financial Statement Report and Corporate Governance Statement 2015 published Biotie Therapies Corp.’s (Nasdaq Helsinki BTH1V; NASDAQ: BITI) (“Biotie” or the “Company”) Financial Statement Report for the financial period ended 31 December 2015 and Corporate Governan |
|
| March 22, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant’s name into English) |
|
| March 22, 2016 |
EX-99.(A)(5)(B) 3 d140641dex99a5b.htm EX-99.(A)(5)(B) Exhibit (a)(5)(B) ACORDA THERAPEUTICS, INC. PRESS RELEASE 22 March 2016 at 2:00 pm (EET) / 8:00 am (New York Time) ACORDA THERAPEUTICS, INC. SUPPLEMENTS THE TENDER OFFER DOCUMENT RELATING TO THE VOLUNTARY PUBLIC TENDER OFFER FOR ALL OF THE ISSUED AND OUTSTANDING SHARES, AMERICAN DEPOSITARY SHARES, STOCK OPTIONS, SHARE UNITS AND WARRANTS IN BIOT |
|
| March 22, 2016 |
Biotie Therapies AMENDMENT NO. 2 TO SC TO-T Amendment No. 2 to SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) BIOTIE THERAPIES OYJ (Name of Subject Company (Issuer)) ACORDA THERAPEUTICS, INC. (Name of Filing Person (Offeror)) Ordinary shares, no nominal value (?Ordinary Shares?) Amer |
|
| March 22, 2016 |
ANNEX 1: SUPPLEMENT NO. 2 TO THE TENDER OFFER DOCUMENT EX-99.(a)(1)(N) Exhibit (a)(1)(N) ANNEX 1: SUPPLEMENT NO. 2 TO THE TENDER OFFER DOCUMENT SUPPLEMENT NO. 2 TO THE TENDER OFFER DOCUMENT ISSUED ON 11 MARCH 2016 BY ACORDA THERAPEUTICS, INC. RELATING TO THE VOLUNTARY PUBLIC TENDER OFFER FOR ALL OF THE ISSUED AND OUTSTANDING SHARES, AMERICAN DEPOSITARY SHARES, STOCK OPTIONS, SHARE UNITS AND WARRANTS IN BIOTIE THERAPIES OYJ 22 March 2016 Acorda Therape |
|
| March 18, 2016 |
EX-99.(a)(5)(A) Exhibit (a)(5)(A) ACORDA THERAPEUTICS, INC. PRESS RELEASE 18 March 2016 at 3:00 pm (EET) / 9:00 am (New York Time) ACORDA THERAPEUTICS, INC. SUPPLEMENTS THE TENDER OFFER DOCUMENT RELATING TO THE VOLUNTARY PUBLIC TENDER OFFER FOR ALL OF THE ISSUED AND OUTSTANDING SHARES, AMERICAN DEPOSITARY SHARES, STOCK OPTIONS, SHARE UNITS AND WARRANTS IN BIOTIE THERAPIES CORP. ON 18 MARCH 2016 As |
|
| March 18, 2016 |
ANNEX 1: SUPPLEMENT NO. 1 TO THE TENDER OFFER DOCUMENT EX-99.(A)(1)(M) 2 d157099dex99a1m.htm EX-99.(A)(1)(M) Exhibit (a)(1)(M) ANNEX 1: SUPPLEMENT NO. 1 TO THE TENDER OFFER DOCUMENT SUPPLEMENT NO. 1 TO THE TENDER OFFER DOCUMENT ISSUED ON 11 MARCH 2016 BY ACORDA THERAPEUTICS, INC. RELATING TO THE VOLUNTARY PUBLIC TENDER OFFER FOR ALL OF THE ISSUED AND OUTSTANDING SHARES, AMERICAN DEPOSITARY SHARES, STOCK OPTIONS, SHARE UNITS AND WARRANTS IN BIOTIE THER |
|
| March 18, 2016 |
Biotie Therapies AMENDMENT NO. 1 TO SC TO-T SC TO-T/A 1 d157099dsctota.htm AMENDMENT NO. 1 TO SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) BIOTIE THERAPIES OYJ (Name of Subject Company (Issuer)) ACORDA THERAPEUTICS, INC. (Name of Filing Person (Offeror)) Ordinary shares, no nominal |
|
| March 18, 2016 |
Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 18 March 2016, at 3.40 p.m. (EET) ACORDA SUPPLEMENTS THE TENDER OFFER DOCUMENT RELATING TO THE VOLUNTARY PUBLIC TENDER OFFER ON 18 MARCH 2016 Biotie Therapies Corp. ("Biotie" or the "Company") announced on 10 March 2016 that the Finnish Financial Supervisory Authority has approved the tender offer document (the “Tender Offer Document”) rel |
|
| March 18, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant’s name into English) |
|
| March 18, 2016 |
Biotie Financial Statement Release 2015 Exhibit 99.1 BIOTIE THERAPIES CORP. FINANCIAL STATEMENT RELEASE March 18, 2016 at 9.00 a.m. Biotie Financial Statement Release 2015 Biotie (Nasdaq Helsinki BTH1V; NASDAQ: BITI) announces its financial statement release for the three and twelve month periods ended December 31, 2015. Company Highlights October ? December 2015 ? Tozadenant, Biotie?s lead pipeline program, is in Phase 3 development in |
|
| March 18, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant’s name into English) |
|
| March 11, 2016 |
EX-99.(E)(17) 14 d146395dex99e17.htm EX-99.(E)(17) Exhibit (e)(17) Mehdi Paborji 4 January 2016 Chief Operating Officer Dear Mehdi The Board of Directors of Biotie Therapies Corp (the “Company”) agreed at its meeting on 4 January 2016 that should a transaction for change of control of the company be completed by 30 September 2016 (a “Transaction”) then you would be eligible for the items set out i |
|
| March 11, 2016 |
Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOTIE THERAPIES OYJ (Name of Subject Company) BIOTIE THERAPIES OYJ (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (?Shares?) American Depositary Shares (?ADSs?), each re |
|
| March 11, 2016 |
AMENDMENT TO MANAGING DIRECTOR AGREEMENT EX-99.(E)(11) 8 d146395dex99e11.htm EX-99.(E)(11) Exhibit (e)(11) AMENDMENT TO MANAGING DIRECTOR AGREEMENT By this Amendment Biotie Therapies Corp. (the “Company”) and its Managing Director Timo Veromaa (the “Managing Director”) agree on certain amendments to the Managing Director Agreement signed on 25 May 2005. This Amendment to the Managing Director Agreement enters into force with effect from |
|
| March 11, 2016 |
EX-99.(E)(18) 15 d146395dex99e18.htm EX-99.(E)(18) Exhibit (e)(18) Stephen Bandak 4 January 2016 Chief Medical Officer Dear Stephen The Board of Directors of Biotie Therapies Corp (the “Company”) agreed at its meeting on 4 January 2016 that should a transaction for change of control of the company be completed by 30 September 2016 (a “Transaction”) then you would be eligible for the items set out |
|
| March 11, 2016 |
EX-99.(e)(9) Exhibit (e)(9) BIOTIE THERAPIES CORP. STOCK OPTION PLAN 2016 (the 2016 Option Plan) The Board of Directors of Biotie Therapies Corp. (the Board) has at its meeting on January 4, 2016 resolved, by authorization of the Annual General Meeting of Shareholders of Biotie Therapies Corp. (the Company, and, together with its subsidiaries and affiliates, the Group) on May 26, 2015, a new stock |
|
| March 11, 2016 |
EX-99.(E)(16) 13 d146395dex99e16.htm EX-99.(E)(16) Exhibit (e)(16) David Cook 4 January 2016 Chief Financial Officer Dear David The Board of Directors of Biotie Therapies Corp (the “Company”) agreed at its meeting on 4 January 2016 that should a transaction for change of control of the company be completed by 30 September 2016 (a “Transaction”) then you would be eligible for the items set out in t |
|
| March 11, 2016 |
EMPLOYEE PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT EX-99.(e)(14) Exhibit (e)(14) March 19, 2015 Stephen Bandak, M.D. 1310 Jones Street San Francisco, CA 94109 Dear Steve: As you know, you have been serving as the Chief Medical Officer of Biotie Therapies, Inc. (the ?Company?) pursuant to a March 28, 2007 offer letter from the Company. The Company has agreed to certain amended terms of employment for you, and thus is issuing you this amended and re |
|
| March 11, 2016 |
EX-99.(e)(12) Exhibit (e)(12) PRIVATE & CONFIDENTIAL DATED: 2 January 2013 DAVID COOK and BIOTIE THERAPIES CORP. EXECUTIVE SERVICE AGREEMENT 1. Appointment 1 2. Duration of the Employment 1 3. Scope of the Employment 3 4. Hours and place of work 5 5. Obligations of the Executive 5 6. Remuneration 6 7. Benefits and Share Options 6 8. Expenses 8 9. Holiday 8 10. Pension, life and other insurance arr |
|
| March 11, 2016 |
EX-99.(e)(10) Exhibit (e)(10) UNOFFICIAL TRANSLATION FROM FINNISH CEO AGREEMENT Biotie Therapies Corp. (the ?Company?) and Timo Veromaa (the ?President and CEO?) have today entered into the following CEO Agreement (the ?Agreement?). 1. POSITION The Company has engaged the President and CEO to act as the Company?s president and CEO under the terms specified in this Agreement and in accordance with |
|
| March 11, 2016 |
STATEMENT OF THE BOARD OF DIRECTORS OF BIOTIE THERAPIES CORP. EX-99.(A)(1)(M) 2 d146395dex99a1m.htm EX-99.(A)(1)(M) Exhibit (a)(1)(M) STATEMENT OF THE BOARD OF DIRECTORS OF BIOTIE THERAPIES CORP. REGARDING THE VOLUNTARY PUBLIC TENDER OFFER BY ACORDA THERAPEUTICS, INC. Acorda Therapeutics, Inc. (hereinafter the “Offeror” or “Acorda”) and Biotie Therapies Corp. (hereinafter “Biotie” or the “Company”) have announced a voluntary public tender offer (the “Offer”) |
|
| March 11, 2016 |
EX-99.(e)(4) Exhibit (e)(4) SYNOSIA THERAPEUTICS HOLDING LTD Amended 2008 STOCK OPTION INCENTIVE PLAN ADOPTED BY THE BOARD: 31 January 2011 TERMINATION DATE: 17 June 2018 The Company, its shareholders and warrant holders and Biotie Therapies Corp. have entered into a Combination Agreement dated 10 January 2010 under which they agreed to combine the business of Biotie Therapies Corp. and the Compan |
|
| March 11, 2016 |
TERMS AND CONDITIONS OF 2014—2016 SHARE UNIT AWARDS EX-99.(E)(7) 4 d146395dex99e7.htm EX-99.(E)(7) Exhibit (e)(7) BIOTIE THERAPIES CORP. EQUITY INCENTIVE PLAN 2014 (the 2014 Equity Plan) The Annual General Meeting of Shareholders of Biotie Therapies Corp. (the Company, or together with its subsidiaries the Group) held on 4 April 2013 authorised the Board of Directors of Biotie Therapies Corp. (the Board) to decide on the issuance of options and oth |
|
| March 11, 2016 |
EMPLOYEE PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT EX-99.(e)(13) Exhibit (e)(13) December 27, 2013 Mehdi Paborji, Ph.D. 10351 Byrne. Avenue Cupertino, CA 95014 Dear Mehdi: We are pleased to offer you employment with Biotie Therapies., Inc. (the ?Company?) as our Chief Operating Officer under the terms set forth herein. If you accept this offer, we would like you to start no later than 6th of January 2014. You will serve as Chief Operating Officer, |
|
| March 11, 2016 |
President and Chief Executive Officer EX-99.(e)(15) Exhibit (e)(15) Dr Timo Veromaa 4 January 2016 President and Chief Executive Officer Dear Timo The Board of Directors of Biotie Therapies Corp (the Company) agreed at its meeting on 4 January 2016 that should a transaction for change of control of the company be completed by 30 September 2016 (a Transaction) then you would be eligible for the items set out in this letter below. T |
|
| March 11, 2016 |
Indemnification Agreement January 2016 BIOTIE THERAPIES CORP. EX-99.(e)(19) Exhibit (e)(19) Indemnification Agreement January 2016 Between BIOTIE THERAPIES CORP. and [?] TABLE OF CONTENTS BACKGROUND 3 1 DEFINITIONS 4 2 SERVICES BY INDEMNITEE 6 3 INDEMNFICATION 6 3.1 General 6 3.2 Witness Expenses 7 3.3 Expenses as a Party Where Wholly or Partly Successful 7 3.4 Exclusions 7 4 ADVANCEMENT OF EXPENSES; DEFENSE OF CLAIMS 8 4.1 Advances 8 4.2 Defense of Claims 8 |
|
| March 11, 2016 |
EX-99.(e)(8) Exhibit (e)(8) BIOTIE THERAPIES CORP. STOCK OPTION PLAN 2014 (the 2014 Option Plan) The Annual General Meeting of Shareholders of Biotie Therapies Corp. (the Company, or together with its subsidiaries the Group) held on 4 April 2013 authorised the Board of Directors of Biotie Therapies Corp. (the Board) to decide on the issuance of options and other rights entitling to shares. The Boa |
|
| March 11, 2016 |
EX-99.(a)(1)(a) Table of Contents Exhibit (a)(1)(A) TENDER OFFER DOCUMENT PUBLIC TENDER OFFER BY ACORDA THERAPEUTICS, INC. Offer to Purchase for Cash All outstanding ordinary shares, no nominal value, All outstanding American Depositary Shares, each representing 80 ordinary shares, no nominal value, All outstanding option rights issued under the December 6, 2011 option plan, All outstanding option |
|
| March 11, 2016 |
SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BIOTIE THERAPIES OYJ (Name of Subject Company (Issuer)) ACORDA THERAPEUTICS, INC. (Name of Filing Person (Offeror)) Ordinary shares, no nominal value (?Ordinary Shares?) American Depositary Shares (?ADSs?), each |
|
| March 10, 2016 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES 1934 ACT OF 1934 BIOTIE THERAPIES OYJ (Name of Subject Company) BIOTIE THERAPIES OYJ (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (?Shares?) American Depositary Shares (?ADSs?), each representing 80 Shares O |
|
| March 10, 2016 |
Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 10 March 2016, 5.45 p.m. THE FINNISH FINANCIAL SUPERVISORY AUTHORITY HAS APPROVED THE TENDER OFFER DOCUMENT, ACORDA WILL COMMENCE THE VOLUNTARY PUBLIC TENDER OFFER ON 11 MARCH 2016 Biotie Therapies Corp. ("Biotie" or the "Company") has announced on 19 January 2016 that the Company and Acorda Therapeutics, Inc. ("Acorda") have entered into |
|
| March 10, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) 6-K 1 dp641746k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of reg |
|
| March 10, 2016 |
EX-99.1 2 d135806dex991.htm EX-99.1 Exhibit 99.1 ACORDA THERAPEUTICS, INC. PRE-COMMENCEMENT RELEASE 10 March 2016 at 4:00 pm (EET) / 9:00 am (New York Time) THE TENDER OFFER DESCRIBED IN THIS RELEASE HAS NOT YET COMMENCED AND THIS RELEASE IS NEITHER AN OFFER TO PURCHASE NOR A SOLICITATION OF AN OFFER TO SELL SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR IN |
|
| March 10, 2016 |
SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BIOTIE THERAPIES OYJ (Name of Subject Company (Issuer)) ACORDA THERAPEUTICS, INC. (Name of Filing Person (Offeror)) Ordinary shares, no nominal value (?Ordinary Shares?) American Depositary Shares (?ADSs?), each |
|
| March 4, 2016 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES 1934 ACT OF 1934 BIOTIE THERAPIES OYJ (Name of Subject Company) BIOTIE THERAPIES OYJ (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), each representing 80 Shares O |
|
| March 4, 2016 |
CHANGE IN THE TIME OF BIOTIE THERAPIES’ ANNUAL GENERAL MEETING 2016 EX-99.2 3 dp64041ex9902.htm EXHIBIT 99.2 Exhibit 99.2 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 4 March 2016, 6.40 p.m. CHANGE IN THE TIME OF BIOTIE THERAPIES’ ANNUAL GENERAL MEETING 2016 Due to the announced tender offer by Acorda Therapeutics, Inc. to purchase all of the issued and outstanding shares, American Depositary Shares, stock options, share units and warrants in Biotie Therapies Cor |
|
| March 4, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant’s name into English) |
|
| March 4, 2016 |
Exhibit 99.1 BIOTIE THERAPIES CORP STOCK EXCHANGE RELEASE 4 March 2016, 7.15 p.m. STATEMENT OF THE BOARD OF DIRECTORS OF BIOTIE THERAPIES CORP. REGARDING THE VOLUNTARY PUBLIC TENDER OFFER BY ACORDA THERAPEUTICS, INC. Acorda Therapeutics, Inc. (hereinafter the ?Offeror? or ?Acorda?) and Biotie Therapies Corp. (hereinafter ?Biotie? or the ?Company?) have announced a voluntary public tender offer (th |
|
| March 3, 2016 |
SC TO-C 1 d153253dsctoc.htm SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BIOTIE THERAPIES OYJ (Name of Subject Company (Issuer)) ACORDA THERAPEUTICS, INC. (Name of Filing Person (Offeror)) Ordinary shares, no nominal value (“Ordinary Shares”) American Depo |
|
| March 3, 2016 |
EX-99.1 Exhibit 99.1 CONTACT Felicia Vonella Acorda Therapeutics (914) 326-5146 [email protected] FOR IMMEDIATE RELEASE Acorda Has Filed Tender Offer Document Relating to Public Tender Offer For Biotie Therapies with Finnish Financial Supervisory Authority ARDSLEY, N.Y. March 3, 2016 As announced on January 19, 2016, Acorda Therapeutics, Inc. (Nasdaq: ACOR) (Acorda) and Biotie Therapies Co |
|
| March 3, 2016 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES 1934 ACT OF 1934 BIOTIE THERAPIES OYJ (Name of Subject Company) BIOTIE THERAPIES OYJ (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (?Shares?) American Depositary Shares (?ADSs?), each representing 80 Shares O |
|
| March 3, 2016 |
Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 3 March 2016, 9.00 a.m. ACORDA HAS FILED THE DRAFT TENDER OFFER DOCUMENT RELATING TO ITS PUBLIC TENDER OFFER FOR BIOTIE THERAPIES WITH THE FINNISH FINANCIAL SUPERVISORY AUTHORITY Biotie Therapies Corp. ("Biotie" or the "Company") announced on 19 January 2016 that the Company and Acorda Therapeutics, Inc. ("Acorda") had entered into a combi |
|
| March 3, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant’s name into English) |
|
| February 19, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant?s name into Englis |
|
| February 19, 2016 |
Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE February 19, 2016 at 3.15 p.m. Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act Biotie Therapies Corp. (Nasdaq Helsinki BTH1V; NASDAQ: BITI) ("Biotie" or the "Company") has on February 19, 2016 received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act, according to whic |
|
| February 17, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BIOTIE THERAPIES OYJ (Name of Subject Company (Issuer)) ACORDA THERAPEUTICS, INC. (Name of Filing Person (Offeror)) Ordinary shares, no nominal value (Ordinary Shares) American Depositary Shares (ADSs), each represe |
|
| February 17, 2016 |
EX-99.1 2 d145327dex991.htm EX-99.1 Exhibit 99.1 CONTACT Felicia Vonella Acorda Therapeutics (914) 326-5146 [email protected] FOR IMMEDIATE RELEASE Acorda Announces Expiration of the Hart-Scott-Rodino Waiting Period for its Tender Offer for Biotie Therapies ARDSLEY, N.Y. – February 17, 2016 – Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the waiting period under the Hart-Scott-Ro |
|
| February 17, 2016 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES 1934 ACT OF 1934 BIOTIE THERAPIES OYJ (Name of Subject Company) BIOTIE THERAPIES OYJ (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (?Shares?) American Depositary Shares (?ADSs?), each representing 80 Shares O |
|
| February 17, 2016 |
BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 17 February 2016, 09:00 a.m. Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 17 February 2016, 09:00 a.m. U.S. antitrust regulation waiting period relating to tender offer has expired Biotie Therapies Corp. ("Biotie" or the "Company") has announced on 19 January 2016 that the Company and Acorda Therapeutics, Inc. ("Acorda") have entered into a combination agreement whereby Acorda will make a public tender offer to |
|
| February 17, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant?s name into Englis |
|
| February 16, 2016 |
BITI / Biotie Therapies Corp. / Vivo Capital VIII, LLC - SC 13G Passive Investment SC 13G SCHEDULE 13G Under the Securities Exchange Act of 1934 Biotie Therapies Corp. |
|
| February 12, 2016 |
Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE February 12, 2016 at 1:15 p.m. Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act Biotie Therapies Corp. (Nasdaq Helsinki BTH1V; NASDAQ: BITI) ("Biotie" or the "Company") has on February 11, 2016 received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act, according to whic |
|
| February 12, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant?s name into Englis |
|
| January 20, 2016 |
BITI / Biotie Therapies Corp. / Baupost Group LLC/MA - NONE Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Biotie Therapies Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 09074D103 (CUSIP Number) Seth A. Klarman, The Baupost Group, L.L.C. 10 St. James Avenue, Suite 1700, Boston, Massachusetts 02116 Phone : (617) 210-8300 (Name, Address |
|
| January 20, 2016 |
EXHIBIT C EXECUTION VERSION January 19, 2016 TO: Acorda Therapeutics, Inc. 420 Saw Mill River Road, Ardsley, NY 10502 Re: Undertaking Dear Sirs, We the undersigned (“we”, “us”, “our” or “ourselves”) refer to the Combination Agreement, dated as of the date hereof (the “Combination Agreement”), which provides for, among other things, your proposed acquisition of all of the outstanding shares, Americ |
|
| January 20, 2016 |
EXHIBIT A JOINT FILING AGREEMENT In accordance with Rule 13d-1 (k)(I) under the Securities Exchange Act of 1934, as amended, each of the undersigned Reporting Persons hereby agrees to the joint filing, along with all other such Reporting Persons, on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to beneficial ownership of shares of Common Stock of Biotie Therapies Corp. |
|
| January 19, 2016 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES 1934 ACT OF 1934 BIOTIE THERAPIES OYJ (Name of Subject Company) BIOTIE THERAPIES OYJ (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (?Ordinary Shares?) American Depositary Shares (?ADSs?), each representing 80 |
|
| January 19, 2016 |
EX-99.1 Exhibit 99.1 INVESTORS MEDIA Felicia Vonella Jeff Macdonald Acorda Therapeutics Acorda Therapeutics (914) 326-5146 (914) 326-5232 [email protected] [email protected] FOR IMMEDIATE RELEASE Acorda to Acquire Biotie Therapies ? Obtains global rights to Phase 3 Parkinson?s disease treatment and additional clinical-stage assets ? Positions Acorda as a leader in Parkinson?s disease therape |
|
| January 19, 2016 |
SUBJECT: Today?s Announcement! EX-99.4 Exhibit 99.4 SUBJECT: Today?s Announcement! Fellow Acordans: I?m excited to let you know that this morning we announced an agreement to purchase Biotie Therapies, a Finland- and San Francisco-based biotechnology company that is developing novel neuroscience compounds. These compounds include a Phase 3 medication for Parkinson?s disease, tozadenant, with the potential for an NDA filing by t |
|
| January 19, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 19, 2016 Acorda Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50513 13-3831168 (State or other jurisdiction (Commission (I.R. |
|
| January 19, 2016 |
EX-99.1 Exhibit 99.1 INVESTORS MEDIA Felicia Vonella Jeff Macdonald Acorda Therapeutics Acorda Therapeutics (914) 326-5146 (914) 326-5232 [email protected] [email protected] FOR IMMEDIATE RELEASE Acorda to Acquire Biotie Therapies ? Obtains global rights to Phase 3 Parkinson?s disease treatment and additional clinical-stage assets ? Positions Acorda as a leader in Parkinson?s disease therape |
|
| January 19, 2016 |
Combination Agreement Acorda Therapeutics, Inc. Biotie Therapies Corp. 19 January 2016 EX-2.1 2 d112870dex21.htm EX-2.1 Exhibit 2.1 EXECUTION VERSION Combination Agreement between Acorda Therapeutics, Inc. and Biotie Therapies Corp. 19 January 2016 i Table of Contents Contents 1. Definitions 3 2. Tender Offer 11 2.1 Launch of the Tender Offer 11 2.2 Consideration 13 2.3 Conditions to completion 14 2.4 Permission by the Board of Directors of the Company to transfer Outstanding Equity |
|
| January 19, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant?s name into English |
|
| January 19, 2016 |
1 Project Christmas Employee Presentation 19 January 2016 Confidential – not for distribution Exhibit 99.2 1 Project Christmas Employee Presentation 19 January 2016 Confidential ? not for distribution 2 CAUTIONARY STATEMENT REGARDING FORWARD - LOOKING STATEMENTS SOME OF THE STATEMENTS CONTAINED IN THIS ANNOUNCEMENT ARE FORWARD - LOOKING STATEMENTS, INCLUDING STATEMENTS REGARDING THE EXPECTED CONSUMMATION OF THE ACQUISITION, WHICH INVOLVES A NUMBER OF RISKS AND UNCERTAINTIES, INCLUDING THE |
|
| January 19, 2016 |
BIOTIE STOCK EXCHANGE RELEASE 19 January 2016 at 9:45 a.m. (EET) Exhibit 99.2 BIOTIE STOCK EXCHANGE RELEASE 19 January 2016 at 9:45 a.m. (EET) ACORDA ANNOUNCES A RECOMMENDED CASH TENDER OFFER FOR ALL SHARES, ADSs AND OTHER EQUITY INSTRUMENTS IN BIOTIE Acorda Therapeutics, Inc. (?Acorda?) and Biotie Therapies Corp. (?Biotie? or the ?Company?) have today entered into a combination agreement (?Combination Agreement?) whereby Acorda, either directly or through a wh |
|
| January 19, 2016 |
CONFIDENTIAL – NOT FOR COPY OR DISTRIBUTION Exhibit 99.1 CONFIDENTIAL ? NOT FOR COPY OR DISTRIBUTION PRE-CALL SCRIPT FOR TIMO First of all, thank you for making time at rather short notice to attend this call. I appreciate that it is a rather inconvenient time, especially for those of you in the US who are at the end of day?s holiday. However, I wanted the opportunity to tell you in advance about a stock exchange release that will be made i |
|
| January 19, 2016 |
Combination Agreement Acorda Therapeutics, Inc. Biotie Therapies Corp. 19 January 2016 Exhibit 99.1 EXECUTION VERSION Combination Agreement between Acorda Therapeutics, Inc. and Biotie Therapies Corp. 19 January 2016 Table of Contents Contents 1. Definitions 3 2. Tender Offer 11 2.1 Launch of the Tender Offer 11 2.2 Consideration 13 2.3 Conditions to completion 14 2.4 Permission by the Board of Directors of the Company to transfer Outstanding Equity Instruments 15 2.5 Delisting and |
|
| January 19, 2016 |
EX-99.2 3 d113540dex992.htm EX-99.2 Exhibit 99.2 ACORDA PRESS RELEASE 19 January 2016 at 9:45 a.m. (EET) ACORDA ANNOUNCES A RECOMMENDED CASH TENDER OFFER FOR ALL SHARES, ADSs AND OTHER EQUITY INSTRUMENTS IN BIOTIE Acorda Therapeutics, Inc. (“Acorda”) and Biotie Therapies Corp. (“Biotie” or the “Company”) have today entered into a combination agreement (“Combination Agreement”) whereby Acorda, eith |
|
| January 19, 2016 |
Exhibit 99.3 Q&A Transaction Q: How long will the transaction take to close? A: The offer documents are expected to be distributed in approximately 4-6 weeks? time. The initial offer period is 20 banking days, but will be extended if specified conditions to completion of the tender offer are not satisfied at the initial expiration date. Q: During the offer period: what do we do; is it business as |
|
| January 19, 2016 |
EX-99.3 Exhibit 99.3 Exhibit 99.3 Acorda Acquisition of Biotie Therapies January 19, 2016 2 Forward Looking Statement This presentation includes forward-looking statements. All statements, other than statements of historical facts, regarding managements expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties th |
|
| January 19, 2016 |
SC TO-C 1 d113540dsctoc.htm SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BIOTIE THERAPIES OYJ (Name of Subject Company (Issuer)) ACORDA THERAPEUTICS, INC. (Name of Filing Person (Offeror)) Ordinary shares, no nominal value (“Ordinary Shares”) American Depo |
|
| January 5, 2016 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant?s name into English |
|
| January 5, 2016 |
Exhibit 99.1 BIOTIE THERAPIES CORP. Stock Exchange Release January 5, 2016 at 8.50 am The Board of Directors of Biotie Therapies Corp. has Approved Two Year Incentive Plan for Employees The Board of Directors of Biotie Therapies Corp. has approved a new share-based incentive plan, the Stock Option Plan 2016 (the Plan), for the Group?s employees for awards to be made in the period 2016 to 2017. The |
|
| January 5, 2016 |
Issuance of shares pursuant to option and equity incentive plans Exhibit 99.2 BIOTIE THERAPIES CORP. Stock Exchange Release January 5, 2016 at 09.00 am Issuance of shares pursuant to option and equity incentive plans Biotie Therapies Corp. (Nasdaq Helsinki BTH1V; NASDAQ: BITI) ("Biotie" or the "Company") announces that the Board of Directors of Biotie has resolved to issue a total of 2,667,812 new shares to be delivered to employees who are participants of the |
|
| December 22, 2015 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2015 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant?s name into Englis |
|
| December 22, 2015 |
Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE December 22, 2015 at 10.30 a.m. Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act Biotie Therapies Corp. (Nasdaq Helsinki BTH1V; NASDAQ: BITI) ("Biotie" or the "Company") has on December 21, 2015 received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act from Mr. Seth Kla |
|
| December 16, 2015 |
Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE December 16, 2015 at 8.00 a.m. Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act Biotie Therapies Corp. (Nasdaq Helsinki BTH1V; NASDAQ: BITI) ("Biotie" or the "Company") has on December 15, 2015 received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act from Mr. Samuel D. |
|
| December 16, 2015 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) 6-K 1 dp619116k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2015 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of |
|
| December 14, 2015 |
Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act EX-99.1 2 dp61846ex9901.htm EXHIBIT 99.1 Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE December 14, 2015 at 3.00 p.m. Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act Biotie Therapies Corp. (Nasdaq Helsinki BTH1V; NASDAQ: BITI) ("Biotie" or the "Company") has on December 12, 2015 received a notification in accordance with Chapter 9, Section 5 of the Finnish |
|
| December 14, 2015 |
Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act EX-99.3 4 dp61846ex9903.htm EXHIBIT 99.3 Exhibit 99.3 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE December 14, 2015 at 3.10 p.m. Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act Biotie Therapies Corp. (Nasdaq Helsinki BTH1V; NASDAQ: BITI) ("Biotie" or the "Company") has on December 12, 2015 received a notification in accordance with Chapter 9, Section 5 of the Finnish |
|
| December 14, 2015 |
Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act EX-99.2 3 dp61846ex9902.htm EXHIBIT 99.2 Exhibit 99.2 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE December 14, 2015 at 3.05 p.m. Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act Biotie Therapies Corp. (Nasdaq Helsinki BTH1V; NASDAQ: BITI) ("Biotie" or the "Company") has on December 12, 2015 received a notification in accordance with Chapter 9, Section 5 of the Finnish |
|
| December 14, 2015 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2015 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant?s name into Englis |
|
| December 8, 2015 |
Biotie’s financial information in 2016 EX-99.1 2 dp61763ex9901.htm EXHIBIT 99.1 Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE December 8, 2015 at 9:00 a.m. Biotie’s financial information in 2016 Biotie Therapies Corp. (Nasdaq Helsinki BTH1V; NASDAQ: BITI) announce the dates it will disclose financial information in 2016. The Company’s financial statement release for year 2015 will be published on March 18, 2016. Biotie ack |
|
| December 8, 2015 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) 6-K 1 dp617636k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2015 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of |
|
| November 12, 2015 |
Biotie interim report 1 January – 30 September 2015 Exhibit 99.1 BIOTIE THERAPIES CORP. INTERIM REPORT November 12, 2015 at 9.00 a.m. Biotie interim report 1 January ? 30 September 2015 Biotie (Nasdaq Helsinki BTH1V; NASDAQ: BITI) announces its interim report for the three and nine month periods ended September 30, 2015. Company Highlights July ? September 2015 ? Tozadenant, Biotie?s lead pipeline program, advanced into Phase 3 development in Parki |
|
| November 12, 2015 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2015 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant?s name into Englis |
|
| November 10, 2015 |
Biotie to Present at the upcoming Stifel 2015 Healthcare Conference Exhibit 99.1 BIOTIE THERAPIES CORP. Press Release November 10, 2015 at 1.00 pm Biotie to Present at the upcoming Stifel 2015 Healthcare Conference TURKU, Finland, November November 10, 2015 ? Biotie (Nasdaq Helsinki BTH1V; NASDAQ: BITI) today announced that Timo Veromaa, President and Chief Executive Officer, is scheduled to present at the Stifel 2015 Healthcare Conference to be held at The New Yo |
|
| November 10, 2015 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) 6-K 1 dp611186k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2015 Commission File Number: Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant |
|
| November 2, 2015 |
Biotie Therapies Corp. Stock Exchange Release Exhibit 99.1 Biotie Therapies Corp. Stock Exchange Release November 2, 2015 at 9.00 a.m. Change in the number of votes relating to Biotie Therapies Corp.?s shares Biotie Therapies Corp. (Nasdaq Helsinki BTH1V; NASDAQ: BITI) ("Biotie" or the "Company") announces that the Swiss subsidiary of the Company, Biotie Therapies AG (previously Synosia Therapeutics Holding AG and Biotie Therapies Holding AG) |
|
| November 2, 2015 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) 6-K 1 dp608866k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2015 Commission File Number: Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant |
|
| October 7, 2015 |
BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 7 October 2015 at 9 a.m. Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 7 October 2015 at 9 a.m. Issue of new treasury shares of Biotie Therapies Corp without consideration Biotie Therapies Corp. (Nasdaq Helsinki BTH1V; NASDAQ: BITI) (?Biotie? or the ?Company?) announces that, pursuant to the authorization of the Annual General Meeting of Shareholders held on 26 May 2015, the Board of Directors of Biotie has r |
|
| October 7, 2015 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2015 Commission File Number: Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant?s name into English) Joukahai |
|
| September 4, 2015 |
SC 13G/A 1 biti090215a1.htm SCHEDULE 13G AMENDMENT FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Biotie Therapies Oyj (Name of Issuer) Common Stock (Title of Class of Securities) 09074D103 (CUSIP Number) September 2, 2015 (Date of Event Which Requires Filing of this Statement) Check the appro |
|
| August 20, 2015 |
As filed with the Securities and Exchange Commission on August 20, 2015 Registration No. |
|
| August 20, 2015 |
Exhibit 99.1 BIOTIE THERAPIES CORP. INTERIM REPORT 20 August, 2015 at 9.00 a.m. Biotie interim report 1 January ? 30 June 2015 Company Highlights April ? June 2015 ? Biotie raised ?83.3 million gross proceeds from the issue of convertible notes (gross proceeds of ?33.1 million) in May 2015 and from the issue of shares represented by American Depositary Shares (ADS) through a US public offering (gr |
|
| August 20, 2015 |
EXHIBIT 99.4 BIOTIE THERAPIES AG 2008 STOCK OPTION INCENTIVE PLAN ADOPTED BY THE BOARD: 18 June 2008 TERMINATION DATE: 17 June 2018 1. GENERAL 1.1 Eligible Option Recipients. The persons eligible to receive Options are Employees, Directors and Consultants. 1.2 General Purpose. The Company, by means of the Plan, seeks to secure and retain the services of the group of persons eligible to receive Opt |
|
| August 20, 2015 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2015 Commission File Number: Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant?s name into English) Joukahais |
|
| July 21, 2015 |
Biotie announces start of tozadenant Phase 3 Study in Parkinson’s disease EX-99.1 2 dp58063ex9901.htm EXHIBIT 99.1 Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE July 21, 2015 at 09.00 a.m. Biotie announces start of tozadenant Phase 3 Study in Parkinson’s disease Biotie (Nasdaq Helsinki BTH1V; NASDAQ: BITI) announces the start of the Phase 3 clinical study of tozadenant, an investigational adenosine A2a receptor antagonist, in patients with Parkinson's disea |
|
| July 21, 2015 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2015 Commission File Number: Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant?s name into English) Joukahaisen |
|
| July 9, 2015 |
BITI / Biotie Therapies Corp. / Baupost Group LLC/MA - NONE Passive Investment SC 13G 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Biotie Therapies Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 09074D103 (CUSIP Number) June 30, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| June 26, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| June 17, 2015 |
Notification according to Chapter 9, Section 5 of the Finnish Securities Markets Act Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE June 17, 2015 at 6.30 p.m. Notification according to Chapter 9, Section 5 of the Finnish Securities Markets Act Biotie Therapies Corp. (the ?Company? or ?Biotie?) has received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act from Mr. Samuel D. Isaly on behalf of himself, OrbiMed Advisors LLC, Orb |
|
| June 17, 2015 |
Notification according to Chapter 9, Section 5 of the Finnish Securities Markets Act Exhibit 99.7 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE June 17, 2015 at 9.05 p.m. Notification according to Chapter 9, Section 5 of the Finnish Securities Markets Act Biotie Therapies Corp. (the ?Company?) has today received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act from UCB S.A. (?UCB?). The notification refers to the underwriting agreement t |
|
| June 17, 2015 |
Notification according to Chapter 9, Section 5 of the Finnish Securities Markets Act Exhibit 99.3 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE June 17, 2015 at 6.40 p.m. Notification according to Chapter 9, Section 5 of the Finnish Securities Markets Act Biotie Therapies Corp. (the ?Company? or ?Biotie?) has today received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act from Seth Klarman on behalf of himself, SAK Corporation and The Ba |
|
| June 17, 2015 |
Notification according to Chapter 9, Section 5 of the Finnish Securities Markets Act Exhibit 99.5 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE June 17, 2015 at 8.45 p.m. Notification according to Chapter 9, Section 5 of the Finnish Securities Markets Act Biotie Therapies Corp. (the ?Company?) has today received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act from FMR LLC concerning changes in share ownership described below. The Compan |
|
| June 17, 2015 |
Notification according to Chapter 9, Section 5 of the Finnish Securities Markets Act Exhibit 99.4 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE June 17, 2015 at 6.45 p.m. Notification according to Chapter 9, Section 5 of the Finnish Securities Markets Act Biotie Therapies Corp. (the ?Company? or ?Biotie?) has received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act from Versant Ventures V, LLC on behalf of itself and Versant Venture Cap |
|
| June 17, 2015 |
Notification according to Chapter 9, Section 5 of the Finnish Securities Markets Act Exhibit 99.2 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE June 17, 2015 at 6.35 p.m. Notification according to Chapter 9, Section 5 of the Finnish Securities Markets Act Biotie Therapies Corp. (the ?Company? or ?Biotie?) has received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act from Vivo Capital VIII, LLC on behalf of itself and Vivo Capital Fund VI |
|
| June 17, 2015 |
Notification according to Chapter 9, Section 5 of the Finnish Securities Markets Act Exhibit 99.6 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE June 17, 2015 at 8.50 p.m. Notification according to Chapter 9, Section 5 of the Finnish Securities Markets Act Biotie Therapies Corp. (the ?Company?) has today received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act from Invesco Ltd. on behalf of itself and Invesco Asset Management Ltd. Accord |
|
| June 17, 2015 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) 6-K 1 dp571996k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2015 Commission File Number: Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant’s n |
|
| June 16, 2015 |
BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE June 16, 2015 at 5.05 p.m. EX-99.3 4 dp57159ex9903.htm EXHIBIT 99.3 Exhibit 99.3 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE June 16, 2015 at 5.05 p.m. Not for release, publication or distribution, directly or indirectly, in whole or in part, in or into the United States, Australia, Canada, Japan or South Africa. Biotie Publishes Listing Prospectus in Finland Biotie Therapies Corp. (“Biotie” or the “Company”), a specializ |
|
| June 16, 2015 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) 6-K 1 dp571596k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 16, 2015 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant’s name |
|
| June 16, 2015 |
BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 16 June 2015 at 10.00 a.m. EX-99.1 2 dp57159ex9901.htm EXHIBIT 99.1 Exhibit 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 16 June 2015 at 10.00 a.m. Notification according to Chapter 9, Section 5 of the Finnish Securities Markets Act Biotie Therapies Corp. (the “Company” or “Biotie”) has received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act from UCB S.A. (“UCB”). The noti |
|
| June 16, 2015 |
BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE June 16, 2015 at 4.55 EET EX-99.2 3 dp57159ex9902.htm EXHIBIT 99.2 Exhibit 99.2 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE June 16, 2015 at 4.55 EET Biotie Announces Closing of U.S. Public Offering and Conversion of Convertible Notes Biotie Therapies Corp. (“Biotie” or the “Company”), a specialized drug development company focused on products for neurodegenerative and psychiatric disorders, has today closed its U.S. pub |
|
| June 15, 2015 |
Biotie Therapies FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 15, 2015 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant?s name into English) Joukahaisenkatu |
|
| June 15, 2015 |
BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE June 12, 2015 at 5.30 p.m. EX-99.2 3 dp57102ex9902.htm EXHIBIT 99.2 Exhibit 99.2 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE June 12, 2015 at 5.30 p.m. Biotie Announces Exercise of Over-allotment Option Biotie Therapies Corp. (“Biotie” or the “Company”), a specialized drug development company focused on products for neurodegenerative and psychiatric disorders, has received information that the underwriters have exercised |
|
| June 15, 2015 |
BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE June 12, 2015 at 10.15 p.m. Exhibit 99.3 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE June 12, 2015 at 10.15 p.m. Notification according to Chapter 9, Section 5 of the Finnish Securities Markets Act Biotie Therapies Corp. (the ?Company? or ?Biotie?) has today received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act from Seth Klarman on behalf of himself, SAK Corporation and The B |
|
| June 15, 2015 |
BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE June 12, 2015 at 10.45 p.m. Exhibit 99.4 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE June 12, 2015 at 10.45 p.m. Notification according to Chapter 9, Section 5 of the Finnish Securities Markets Act Biotie Therapies Corp. (the ?Company?) has today received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act from FMR LLC concerning an arrangement that, if realized, would result in the |
|
| June 15, 2015 |
Biotie Therapies Corp. Stock Exchange Release 12 J EX-99.1 2 dp57102ex9901.htm EXHIBIT 99.1 Exhibit 99.1 Biotie Therapies Corp. Stock Exchange Release 12 June, 2015 at 5.15 p.m. Change in the number of votes relating to Biotie Therapies Corp.’s shares The Swiss subsidiary of Biotie Therapies Corp. ("Biotie" or the "Company"), Biotie Therapies AG (previously Synosia Therapeutics Holding AG and Biotie Therapies Holding AG) has conveyed Biotie shares |
|
| June 12, 2015 |
424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-204147 and 333-204707 PROSPECTUS 3,761,418 American Depositary Shares Representing 300,913,440 Shares BIOTIE THERAPIES CORP. (incorporated in the Republic of Finland) We are offering 3,761,418 ADSs, at a public offering price of $14.888 per ADS. The last reported sales price of our shares on the NASDAQ OMX Helsinki Ltd. |
|
| June 11, 2015 |
BIOTIE THERAPIES CORP. FREE WRITING PROSPECTUS FWP Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated June 11, 2015 Relating to Preliminary Prospectus dated June 8, 2015 Registration No. |
|
| June 10, 2015 |
Form F-1/A As filed with the Securities and Exchange Commission on June 10, 2015 Registration No. |
|
| June 10, 2015 |
Form 8-A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOTIE THERAPIES OYJ (Exact Name of Registrant as Specified in Its Charter) Republic of Finland Not Applicable (State of Incorporation or Organization) (I.R.S. Employer Identification No |
|
| June 10, 2015 |
CORRESP New York Menlo Park Washington DC S?o Paulo London Paris Madrid Tokyo Beijing Hong Kong Sophia Hudson Davis Polk & Wardwell LLP 450 Lexington Avenue New York, NY 10017 212 450 4762 tel 212 701 5762 fax sophia. |
|
| June 8, 2015 |
Biotie Therapies AMENDMENT NO. 2 TO FORM F-1 Amendment No. 2 to Form F-1 Table of Contents As filed with the Securities and Exchange Commission on June 8, 2015 Registration No. 333-204147 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOTIE THERAPIES OYJ (Exact name of Registrant as specified in Its charter) Biotie Therapies Corp. (T |
|
| June 8, 2015 |
June 8, 2015 Re: Biotie Therapies Corp. Registration Statement on Form F-1 Registration No. 333-204147 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Ladies and Gentlemen: In accordance with Rule 461 and Rule 430A under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the effective date for the Reg |
|
| June 8, 2015 |
BIOTIE THERAPIES CORP. FREE WRITING PROSPECTUS FWP Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated June 8, 2015 Relating to Preliminary Prospectus dated June 8, 2015 Registration No. |
|
| June 8, 2015 |
RBC Capital Markets, LLC 200 Vesey Street, 8th Floor New York, NY 10281 Stifel, Nicolaus & Company, Incorporated 237 Park Ave, 8th Floor New York, NY 10017 June 8, 2015 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| June 4, 2015 |
CORRESP New York Menlo Park Washington DC S?o Paulo London Paris Madrid Tokyo Beijing Hong Kong Sophia Hudson Davis Polk & Wardwell LLP 450 Lexington Avenue New York, NY 10017 212 450 4762 tel 212 701 5762 fax sophia. |
|
| June 4, 2015 |
BIOTIE THERAPIES CORP. FREE WRITING PROSPECTUS FWP Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated June 4, 2015 Relating to Preliminary Prospectus dated June 4, 2015 Registration No. |
|
| June 4, 2015 |
Biotie Therapies AMENDMENT NO. 1 TO FORM F-1 Amendment No. 1 to Form F-1 Table of Contents As filed with the Securities and Exchange Commission on June 4, 2015 Registration No. 333-204147 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOTIE THERAPIES OYJ (Exact name of Registrant as specified in Its charter) Biotie Therapies Corp. (T |
|
| May 14, 2015 |
F-1 1 d881786df1.htm FORM F-1 Table of Contents As filed with the Securities and Exchange Commission on May 13, 2015 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOTIE THERAPIES OYJ (Exact name of Registrant as specified in Its charter) Biotie Therapies Corp. (Translation of Registran |
|
| May 13, 2015 |
Response Letter New York Menlo Park Washington DC S?o Paulo London Paris Madrid Tokyo Beijing Hong Kong Sophia Hudson Davis Polk & Wardwell LLP 450 Lexington Avenue New York, NY 10017 212 450 4762 tel 212 701 5762 fax sophia. |
|
| April 21, 2015 |
New York Menlo Park Washington DC São Paulo London Paris Madrid Tokyo Beijing Hong Kong Sophia Hudson Davis Polk & Wardwell LLP 450 Lexington Avenue New York, NY 10017 212 450 4762 tel 212 701 5762 fax sophia. |
|
| April 21, 2015 |
DRS F-1 Table of Contents As submitted confidentially with the Securities and Exchange Commission on April 21, 2015 This amendment no. |
